In conclusion, coexisting mutations in SMAD4 and TP53 are associated with worse overall survival than concurrent TP53 wild-type SMAD4 mutation patients with metastatic colorectal cancer. The gene discussed is SMAD4; the disease is metastatic colorectal cancer.